Global Non-Insulin Diabetes Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Non-Insulin Diabetes Therapeutics Market was valued at $62.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 11.5% CAGR, to an estimated market size of $108 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global non-insulin diabetes therapeutics market comprises pharmaceutical agents used to manage Type 2 Diabetes Mellitus (T2DM) by improving glycemic control without the use of insulin. The scope includes GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, biguanides (metformin), and other oral or injectable non-insulin agents, while excluding insulin delivery devices and insulin-based therapies.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Non-Insulin Diabetes Therapeutics Market in the period 2025-30:
- The market is experiencing a paradigm shift from simple glucose lowering to a holistic approach that prioritizes cardiorenal protection and weight management.
- Rapid adoption of dual GLP-1/GIP agonists is significantly expanding the market value due to superior efficacy in both glycemic control and obesity treatment.
- Increasing utilization of real-world data from cardiovascular outcome trials is influencing clinical guidelines and securing favorable insurance formulary placements.
- The development of oral formulations for traditionally injectable peptide therapies is expected to drastically improve patient adherence and market penetration.
- Rising prevalence of Type 2 Diabetes in emerging economies, particularly China and India, is driving high-volume growth and local manufacturing initiatives.
- Integration of digital health platforms and AI-driven monitoring is enhancing personalized treatment regimens and remote patient management.
- Strategic M&A activity and heavy R&D investment are focused on next-generation agents with longer durations of action and fewer side effects.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- GLP-1 Receptor Agonists
- SGLT2 Inhibitors
- DPP-4 Inhibitors
- Biguanides & Others